These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 7899583

  • 1. Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3.
    Djukanović L, Pejanović S, Dragojlović Z, Stosović M.
    Ren Fail; 1994 Nov; 16(6):715-23. PubMed ID: 7899583
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) and 1, 24 Dihydroxycholecalciferol (1, 24(OH)2D3).
    Shiraki M, Orimo H, Ito H, Akiguchi I, Nakao J, Takahashi R, Ishizuka S.
    Endocrinol Jpn; 1985 Apr; 32(2):305-15. PubMed ID: 2995014
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism. A pilot study].
    Matuszkiewicz-Rowińska J, Niemczyk S, Bogdańska-Straszyńska B, Ostrowski K.
    Pol Arch Med Wewn; 1993 Feb; 89(2):95-101. PubMed ID: 8502602
    [Abstract] [Full Text] [Related]

  • 6. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
    Brandi L, Daugaard H, Tvedegaard E, Storm T, Olgaard K.
    Nephron; 1989 Feb; 53(3):194-200. PubMed ID: 2797340
    [Abstract] [Full Text] [Related]

  • 7. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
    Matuszkiewicz-Rowińska J, Niemczyk S, Pacocha E, Puka J, Switalski M, Bogdańska-Straszyńska B, Ostrowski K.
    Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
    [Abstract] [Full Text] [Related]

  • 8. Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone.
    Birkenhäger-Frenkel DH, Pols HA, Zeelenberg J, Eijgelsheim JJ, Schot R, Nigg AL, Weimar W, Mulder PG, Birkenhäger JC.
    J Bone Miner Res; 1995 Feb; 10(2):197-204. PubMed ID: 7754799
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
    Tarrass F, Yazidi A, Sif H, Zamd M, Benghanem MG, Ramdani B.
    Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
    [Abstract] [Full Text] [Related]

  • 10. [Evaluation of the treatment efficacy of secondary hyperparathyroidism with oral pulse doses of alphacalcidol].
    Switalski M, Kuriga M, Wańkowicz Z.
    Pol Arch Med Wewn; 1997 Oct; 98(10):358-65. PubMed ID: 9557090
    [Abstract] [Full Text] [Related]

  • 11. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
    Gu Y, Ding F, Chen N, Mei CL, Qian JQ, Wang XY, Shi W, Hou FF, Li XW, Wang M, Chen YP.
    Ren Fail; 2005 Oct; 27(2):205-12. PubMed ID: 15807187
    [Abstract] [Full Text] [Related]

  • 12. [Treatment of secondary hyperparathyroidism with vitamin D metabolites].
    Stojimirović B, Pejanović S, Djukanović Lj.
    Srp Arh Celok Lek; 1994 Oct; 122(7-8):197-9. PubMed ID: 17974384
    [Abstract] [Full Text] [Related]

  • 13. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P, Fournier A, Leflon A, Hervé M, Sebert JL, Grégoire I, Bataille P, Guéris J.
    Nephron; 1985 Oct; 39(4):309-15. PubMed ID: 3982576
    [Abstract] [Full Text] [Related]

  • 14. Acute effect of oral, intraperitoneal, and intravenous 1 alpha-hydroxycholecalciferol on markers of bone metabolism.
    Joffe P, Ladefoged SD, Cintin C, Jensen LT, Hyldstrup L.
    Nephrol Dial Transplant; 1994 Oct; 9(5):524-31. PubMed ID: 8090332
    [Abstract] [Full Text] [Related]

  • 15. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
    Tsukamoto Y, Nomura M, Takahashi Y, Takagi Y, Yoshida A, Nagaoka T, Togashi K, Kikawada R, Marumo F.
    Nephron; 1991 Oct; 57(1):23-8. PubMed ID: 2046811
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K.
    Nephron; 1996 Oct; 74(1):89-103. PubMed ID: 8883025
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration.
    Perez-Mijares R, Gomez-Fernandez P, Almaraz-Jimenez M, Ramos-Diaz M, Rivero-Bohorquez J.
    Am J Nephrol; 1993 Oct; 13(2):149-54. PubMed ID: 8342582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.